ArticleBasic research in cardiology2026
Functional rejuvenation of endothelial cell aging by transient reprogramming.
Article in Basic research in cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Senescent endothelial cells (ECs), characterized by a reduced angiogenic and regenerative potential, are key players in the pathophysiology of cardiovascular diseases. Therefore, targeting these cells has been suggested as an effective therapeutic strategy to increase health. Here, we are the first to report that non-genetic overexpression of the Yamanaka factors induces partial functional rejuvenation and attenuation of senescence-associated features in endothelial cells. Methods to characterize the effects of the transient reprogramming included quantification of gene expression as well as measurements of cellular functions in vitro. Further, in vivo experiments were performed in a hind-limb ischemia model. The application of the pharmacological cocktail to replicative senescent ECs resulted in a robust but timely restricted activation of Oct3/4, Sox2, Klf4, and c-Myc (p < 0.0 and p < 0.01). This was associated with a significant reduction of senescence markers such as p16ink4a and p14arf (p < 0.01). Additionally, qPCR-based telomere length measurements were stabilized, and functional properties of senescent ECs, such as proliferation, migration, sprouting, and tube formation, were improved (p < 0.05). Continuous cultivation of the treated cells over the long term indicated that expression of p16ink4a and p14arf remained significantly low, while cell migration remained enhanced. In vivo, a significantly improved blood flow was observed at 7 and 14 days after hind-limb ischemia in 21 months old C57BL/6 mice (p < 0.001). In conclusion, we revealed that a partial attenuation of endothelial cell senescence-associated features can be induced by a short pharmacological overexpression of the Yamanaka factors. While the compounds used are individually approved for other indications, their combined use in this context highlights a conceptual translational potential, whereas the clinical applicability of this approach remains to be evaluated.
Indexed as
Identifiers
42360485What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.